This global gathering is for the Annual Conference of the Licensing Executives Society International (LESI) – a global organization, founded in 1972, representing more than 6,500 business leaders and professionals through its 33 societies with members from 90 countries.

LIFE SCIENCES Highlight in the LESI2023 Program:

New IP Business Models in Drug Discovery
Main Plenary Panel Session, #1
Monday, May 1, 2023 (9:30-10:30 am)

Discussion Focus: The importance of drugs created using ecosystems and AI to mitigate high-risk drug discovery projects (through technology and IP business alliances).

• Moderator: TBD
• Gordon McCauley, President and CEO, adMare Bioinnovations (Montreal) commercial expertise, R&D infrastructure, seed capital to build strong life sciences companies, robust ecosystems and industry-ready talent.
• Yasunori Yamaguchi, President and CEO, IP Gaia, Japan – provides high probability of success by using hidden seed patents from global pharmaceuticals, research institutions and universities and also provides unique business model of IP licensing and drug development using their ecosystem.
• Charles Gore, Executive Director, Medicines Patent Pool (MPP), Switzerland – executed licensing deals including COVID vaccines with major pharmaceutical players; unique business case (they also received the LES 2022 Deal of Distinction).
• Lloyd Segal, President of Repare Therapeutics Montreal and Boston – public company with CRISPR-enabled SNIPRx platform to discover and develop highly targeted cancer therapies.

BIOTECanada members can use the promo code “MTL100”.

Register today.